Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CIBC Keeps Sector Perform on Dov Pharmaceutical


CIBC World keeps sector perform on Dov Pharmaceutical (DOVP)

Analyst Matt Geller say Dov and Merck are in a licensing deal for DOV 216,303 and DOV 21,947, which are Dov's triple uptake inhibitors for depression, anxiety, and addiction. He notes Dov will get an upfront payment of $35 million, as well as up to $420 million in milestones -- $300 million for for clinical, and regulatory, and $120 million for sales.

Geller believes this news is a strong indication that soon-to-be-released Phase III data for 216,303 are positive. He says, in his view, this adds substantial value to Dov, which he believes is among the best small-cap values in biotech. He has a $23 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus